echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > 2021 American Endocrinology Annual Meeting Express: Insulin injection once a week will become possible!

    2021 American Endocrinology Annual Meeting Express: Insulin injection once a week will become possible!

    • Last Update: 2021-04-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    This year, 2021 is the 100th anniversary of the discovery of insulin.

    The results of a phase 2 clinical trial of ENDO at this year’s annual meeting of the Endocrine Society showed that, compared with once-a-day basal insulin, weekly new basal insulin injections (BIF) showed similar efficacy and safety, and had hypoglycemic episodes.
    The rate is lower.

    Before the discovery of insulin, diabetics could only delay the progression of the disease through strict dietary restrictions, and some patients even died of hunger.

    Until 1921, Canadian scientist Frederick Banting discovered and successfully extracted insulin, which was used in clinical practice in 1922.

    Endocrine Society Twitter screenshots The discovery and application of insulin have saved the lives of a large number of diabetic patients.

    So far, insulin injection is still the main treatment for diabetic patients.

    However, the current insulin injection treatment requires once a day, and many diabetics find it troublesome or fear that they will have to inject insulin every day for their entire lives, so that they have poor compliance with insulin injections, and many patients have not received better treatment for their diabetes.

    Therefore, there is an urgent clinical need for an efficient insulin that does not require daily injections of patients.

    Healthline In this study, a total of 399 diabetic patients participated.
    All patients had type 2 diabetes and had previously used basal insulin and oral anti-diabetic drugs.

    The clinical trial cycle is 32 weeks.

    The researchers compared the effects of basal insulin Fc (BIF) with the commercially available long-acting daily basal insulin preparation degludec in patients with type 2 diabetes.

    Patients were randomly assigned to one of three treatment groups: with two different dosing algorithms (with different targets for fasting blood glucose levels), namely, a weekly injection of BIF, or a daily injection of standard insulin degludec.

    One target for fasting blood glucose for patients receiving BIF is 140 mg/dL or less than 140 mg/dL, and the other target is 120 mg/dL or less.

    The fasting blood glucose target for insulin degludec is 100 mg/dL or less.

    The study’s principal investigator and medical director of the Los Angeles National Institute of California, Dr.
    Juan Frias, pointed out that patients taking BIF achieved similar long-term blood sugar control compared with insulin degludec.

    The data showed that the average hemoglobin A1c of study participants at the beginning of the study was 8.
    1%.
    At the end of the study, the A1c of BIF improved by 0.
    6% on average, and insulin degludec improved by 0.
    7%.

    In addition, the use of BIF significantly reduces the incidence of hypoglycemia (less than 70mg/dL).

    Severe untreated hypoglycemia is a dangerous complication that can lead to seizures, loss of consciousness, and death.

    Frias said that the results of the study show that BIF is promising as a weekly basal insulin and may be a major advancement in insulin therapy.

    Compared with the current daily basal insulin, BIF has a flatter and more predictable action potential, which may be the cause of the lower incidence of hypoglycemia.

    At the same time, it was added that when oral medications alone no longer give adequate blood sugar control, weekly insulin injections increase the willingness of patients with type 2 diabetes to start insulin therapy and improve insulin therapy compliance, which will be more than daily basic insulin therapy.
    Good clinical effect.

    In addition, regarding safety, Frias said that the adverse event profile of BIF is generally comparable to that of insulin degludec.

    Based on the current data, the research has begun to be further carried out in patients with type 1 diabetes and other patients with type 2 diabetes.

    Source: Metz Medical Comprehensive Report authorized to reprint, submit and break the news, please contact Metz Medical Administrator MedSci (WeChat ID: medsci_m) Recommended reading Harvard heavyweight! The HPV vaccine should be given as early as possible, as the anti-cancer effect of 26 years old and above will be reduced! Heavy: 13 latest proposals for the pharmaceutical industry at the National Two Sessions in 2021! Lancet: Heavy! Only 2.
    7% of the Wuhan population produced effective antibodies to the new coronavirus!
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.